Your Account
close button

Use our patient tools for secure, convenient, 24/7 access. Learn more

OR

This facility is a member of


Connect with us:

Lung Cancer Trial

   

Non-Small Cell Lung Cancer

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely-Resected Stage 1B) (>4cm) to IIIA Non-Small Cell Lung Cancer (NSCLC) [ECOG 1505]

 Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N. 
 

A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer [ECOG 3508]  

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N. 

A Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients who will not Receive Bevacizumab-Based Therapy [ECOG 4508]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N. 

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC [ECOG 5508]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N. 

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Cell Lung Cancer after Definitive Chemoradiation [ECOG 6508]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N. 

Small Cell Lung Cancer

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide [CALGB 30610]

 Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N

 

Share